Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 206
- Registration Number
- NCT06107413
- Locations
- 🇧🇪
Universitair Ziekenhuis Leuven /ID# 257079, Leuven, Vlaams-Brabant, Belgium
🇺🇸Highlands Oncology Group, PA /ID# 259424, Springdale, Arkansas, United States
🇺🇸City of Hope National Medical Center /ID# 257576, Duarte, California, United States
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 20
- Registration Number
- NCT06094140
- Locations
- 🇦🇺
GenesisCare North Shore, Sydney, New South Wales, Australia
🇦🇺Wollongong Hospital, Wollongong, New South Wales, Australia
🇦🇺Warringal Private Hospital, Melbourne, Victoria, Australia
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT06089330
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT06013618
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 42
- Registration Number
- NCT06011772
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
A Phase Ib Trial of Eribulin in Combination with Irinotecan and Temozolamide in Children with Relapsed or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT06006273
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Catharina Ziekenhuis Eindhoven
- Target Recruit Count
- 85
- Registration Number
- NCT06003998
- Locations
- 🇳🇱
Catharina Hospital, Eindhoven, Netherlands
🇳🇱Erasmus Medical Centre, Rotterdam, Netherlands
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 105
- Registration Number
- NCT05999994
- Locations
- 🇧🇪
UCL- Saint Luc, Bruxelles, Belgium
🇫🇷Institut Curie, Paris, France
🇳🇱Prinses Maxima Centrum, Utrecht, Netherlands
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT05945823
- Locations
- 🇺🇸
University of California Los Angeles UCLA - Cancer Care - Santa Monica, Santa Monica, California, United States
🇺🇸Rocky Mountain Cancer Centers Midtown, Denver, Colorado, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 408
- Registration Number
- NCT05863195
- Locations
- 🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.